Lucio Luzzatto

Q: What Schools Are Affiliated With Lucio Luzzatto

Lucio Luzzatto is affiliated with the following schools: Royal Postgraduate Medical School, University of Genoa, University of Florence, New York University, Muhimbili University of Health and Allied Sciences, Saarland University, Mahidol University, Washington University in St. Louis, University of Milan, Imperial College London, University of Oxford

Lucio Luzzatto's AcademicInfluence.com Rankings

Lucio Luzzatto

Philosophy

#4486

World Rank

#7020

Historical Rank

Logic

#1926

World Rank

#2798

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Lucio Luzzatto's Degrees

PhD Biochemistry University of Milan

Why Is Lucio Luzzatto Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lucio Luzzatto's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. (2006) (868)
Diagnosis and management of paroxysmal nocturnal hemoglobinuria. (2005) (705)
Targeted disruption of the housekeeping gene encoding glucose 6‐phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. (1995) (539)
Natural history of paroxysmal nocturnal hemoglobinuria. (1995) (529)
Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin (2000) (507)
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. (2007) (506)
Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. (2003) (384)
Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. (1999) (379)
Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG‐A gene. (1994) (360)
Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. (1998) (331)
Somatic Mutations in Paroxysmal Nocturnal Hemoglobinuria: A Blessing in Disguise? (1997) (283)
Hematologically important mutations: glucose-6-phosphate dehydrogenase. (1996) (278)
Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells. (1970) (274)
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. (2009) (272)
Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. (2000) (272)
Glucose-6-Phosphate Dehydrogenase Deficient Red Cells: Resistance to Infection by Malarial Parasites (1969) (244)
Isolation of human glucose-6-phosphate dehydrogenase (G6PD) cDNA clones: primary structure of the protein and unusual 5' non-coding region. (1986) (226)
Replicative aging and gene expression in long-term cultures of human bone marrow stromal cells. (2002) (220)
In vivo telomere dynamics of human hematopoietic stem cells. (1997) (215)
Human CD1d–glycolipid tetramers generated by in vitro oxidative refolding chromatography (2001) (206)
Structural analysis of the X‐linked gene encoding human glucose 6‐phosphate dehydrogenase. (1986) (201)
7 Paroxysmal nocturnal haemoglobinuria (1989) (200)
Increased sickling of parasitised erythrocytes as mechanism of resistance against malaria in the sickle-cell trait. (1970) (187)
Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria (1994) (179)
G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications (2014) (178)
Origin and spread of the glucose-6-phosphate dehydrogenase variant (G6PD-Mediterranean) in the Middle East. (1990) (172)
Glucose-6-phosphate dehydrogenase and malaria. Greater resistance of females heterozygous for enzyme deficiency and of males with non-deficient variant. (1972) (167)
Glucose-6-Phosphate Dehydrogenase Deficiency. (2016) (161)
A quantitative measurement of the human somatic mutation rate. (2005) (160)
TβR-I(6A) Is a Candidate Tumor Susceptibility Allele (1999) (158)
Maternally transmitted severe glucose 6‐phosphate dehydrogenase deficiency is an embryonic lethal (2002) (140)
The molecular basis of glucose-6-phosphate dehydrogenase deficiency. (1992) (140)
Favism and Glucose-6-Phosphate Dehydrogenase Deficiency. (2018) (140)
Sickle Cell Anaemia and Malaria (2012) (134)
Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion. (1997) (133)
Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. (1994) (132)
Genetics of red cells and susceptibility to malaria (1979) (130)
Glucose 6-phosphate dehydrogenase deficiency: from genotype to phenotype. (2006) (130)
The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. (2012) (129)
Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common (2012) (129)
Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. (2000) (124)
Mechanism of action of streptomycin in E. coli: interruption of the ribosome cycle at the initiation of protein synthesis. (1968) (122)
Bone marrow transplants for paroxysmal nocturnal haemoglobinuria (1999) (121)
Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. (1993) (119)
Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry (2016) (119)
Genetics of red cells and susceptibility to malaria. (1979) (119)
Outrageous prices of orphan drugs: a call for collaboration (2018) (114)
New Insights into the Pathophysiology of Acquired Cytopenias. (2000) (110)
LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. (2009) (105)
Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. (1998) (104)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype (2014) (103)
Multiple glucose 6-phosphate dehydrogenase-deficient variants correlate with malaria endemicity in the Vanuatu archipelago (southwestern Pacific). (1995) (103)
Adaptation of Plasmodium falciparum to glucose 6-phosphate dehydrogenase-deficient host red cells by production of parasite-encoded enzyme (1985) (101)
The dual pathogenesis of paroxysmal nocturnal hemoglobinuria (1997) (98)
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. (2012) (98)
Incomplete synthesis of N-glycans in congenital dyserythropoietic anemia type II caused by a defect in the gene encoding alpha-mannosidase II. (1990) (97)
Mutations in the PIG-A gene causing paroxysmal nocturnal hemoglobinuria are mainly of the frameshift type. (1995) (96)
Analysis of β, γ, and δ T‐Cell receptor genes in mycosis fungoides and sezary syndrome (1991) (94)
Identification of a single base change in a new human mutant glucose-6-phosphate dehydrogenase gene by polymerase-chain-reaction amplification of the entire coding region from genomic DNA. (1990) (92)
The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications. (1998) (90)
A transgenic mouse model of sickle cell disorder (1990) (90)
CD157 is an important mediator of neutrophil adhesion and migration. (2004) (90)
Polymorphic sites in the African population detected by sequence analysis of the glucose-6-phosphate dehydrogenase gene outline the evolution of the variants A and A-. (1991) (89)
Variants of glucose‐6‐phosphate dehydrogenase are due to missense mutations spread throughout the coding region of the gene (1993) (89)
Regulation of the activity of glucose-6-phosphate dehydrogenase by NADP+ and NADPH. (1967) (85)
Genetic heterogeneity of glucose-6-phosphate dehydrogenase deficiency revealed by single-strand conformation and sequence analysis. (1993) (85)
Dyskeratosis congenita fibroblasts are abnormal and have unbalanced chromosomal rearrangements. (1992) (84)
TbetaR-I(6A) is a candidate tumor susceptibility allele. (1999) (82)
Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers (2017) (81)
A new glucose-6-phosphate dehydrogenase variant, G6PD Orissa (44 Ala-->Gly), is the major polymorphic variant in tribal populations in India. (1995) (81)
Glucose 6-phosphate dehydrogenase mutations causing enzyme deficiency in a model of the tertiary structure of the human enzyme. (1996) (81)
Advances in understanding the pathogenesis of acquired aplastic anaemia (2018) (81)
Management of Paroxysmal Nocturnal Haemoglobinuria: a personal view (2011) (80)
Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria. (2013) (79)
High-level, erythroid-specific expression of the human alpha-globin gene in transgenic mice and the production of human hemoglobin in murine erythrocytes. (1989) (77)
G6PD Mediterranean accounts for the high prevalence of G6PD deficiency in Kurdish Jews (1993) (77)
Decreased number of circulating BFU-Es in paroxysmal nocturnal hemoglobinuria. (1982) (74)
The cellular pathogenesis of paroxysmal nocturnal haemoglobinuria (2001) (74)
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria (2014) (73)
Heterogeneity of T‐cell beta‐chain gene rearrangements in human leukaemias and lymphomas. (1985) (73)
Cytological mapping of the human glucose-6-phosphate dehydrogenase gene distal to the fragile-X site suggests a high rate of meiotic recombination across this site. (1984) (72)
Mutations in the PIG‐A gene causing partial deficiency of GPI‐linked surface proteins (PNH II) in patients with paroxysmal nocturnal haemoglobinuria (1994) (71)
Human erythrocyte glucose 6-phosphate dehydrogenase: structure and function in normal and mutant subjects. (1978) (70)
Two new cell lines from B‐prolymphocytic leukaemia: Characterization by morphology, immunological markers, karyotype and Ig gene rearrangement (1986) (70)
Dyskeratosis and ribosomal rebellion (1998) (68)
Germline NPM1 mutations lead to altered rRNA 2’-O-methylation and cause dyskeratosis congenita (2019) (68)
Blood group antigens and antibodies in Nigeria. (1974) (68)
Genomic organization of the X-linked gene (PIG-A) that is mutated in paroxysmal nocturnal haemoglobinuria and of a related autosomal pseudogene mapped to 12q21. (1994) (67)
Human mutations in glucose 6‐phosphate dehydrogenase reflect evolutionary history (2000) (67)
Analysis of β, γ, and δ T-cell receptor genes in lymphomatoid papulosis: Cellular basis of two distinct histologic subsets (1991) (66)
Tissue-specific levels of human glucose-6-phosphate dehydrogenase correlate with methylation of specific sites at the 3' end of the gene. (1985) (66)
Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria (1994) (66)
Different properties of glucose 6-phosphate dehydrogenase from human erythrocytes with normal and abnormal enzyme levels. (1965) (65)
Paroxysmal nocturnal hemoglobinuria: an acquired X-linked genetic disease with somatic-cell mosaicism. (2006) (64)
Primaquine-induced haemolysis in females heterozygous for G6PD deficiency (2018) (64)
Paroxysmal nocturnal hemoglobinuria and eculizumab* (2010) (63)
The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics (2010) (63)
Red cell glucose‐6‐phosphate dehydrogenase status and pyruvate kinase activity in a Nigerian population (2000) (61)
Molecular characterization of erythrocyte glucose-6-phosphate dehydrogenase deficiency in Al-Ain District, United Arab Emirates. (1996) (60)
PREGNANCY IN HOMOZYGOUS SICKLE‐CELL ANAEMIA (1972) (59)
Specific methylation pattern at the 3′ end of the human housekeeping gene for glucose 6‐phosphate dehydrogenase. (1984) (57)
Both mutations in G6PD A- are necessary to produce the G6PD deficient phenotype. (1992) (57)
The use of PIG-A as a sentinel gene for the study of the somatic mutation rate and of mutagenic agents in vivo. (2010) (56)
Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab. (2010) (54)
Highly homologous T-cell receptor beta sequences support a common target for autoreactive T cells in most patients with paroxysmal nocturnal hemoglobinuria. (2007) (54)
Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones (2002) (54)
Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancer. (2007) (54)
Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria (2001) (54)
Glucose 6-phosphate dehydrogenase deficiency and sickle cell anemia: frequency and features of the association in an African community. (1975) (53)
Association of clonal T‐cell large granular lymphocyte disease and paroxysmal nocturnal haemoglobinuria (PNH): further evidence for a pathogenetic link between T cells, aplastic anaemia and PNH (2001) (53)
Recent Advances in Biological and Clinical Aspects of Paroxysmal Nocturnal Hemoglobinuria (2006) (53)
G6PD haplotypes spanning Xq28 from F8C to red/green color vision. (1993) (52)
Mild spherocytic hereditary elliptocytosis and altered levels of α- and γ-adducins in β-adducin-deficient mice (2000) (52)
Dyskeratosis congenita is a chromosomal instability disorder. (1994) (52)
Molecular characterization of G6PD deficiency in Oman. (1996) (52)
Neutral evolution in paroxysmal nocturnal hemoglobinuria (2008) (52)
CD157 plays a pivotal role in neutrophil transendothelial migration. (2006) (51)
Purification and properties of human glucose-6-phosphate dehydrogenase made in E. coli. (1992) (51)
Genomic structure and sequence of the Fugu rubripes glucose-6-phosphate dehydrogenase gene (G6PD). (1995) (51)
Red Cell Enzymopathies (1998) (51)
Glucose 6-phosphate dehydrogenase. (1986) (51)
High incidence of thrombosis in African-American and Latin-American patients with Paroxysmal Nocturnal Haemoglobinuria (2004) (50)
Transcriptional Functionality of Germ Line p53 Mutants Influences Cancer Phenotype (2007) (50)
Polyribosome depletion and blockage of the ribosome cycle by streptomycin in Escherichia coli. (1969) (50)
G6PD Canton a common deficient variant in South East Asia caused by a 459 Arg----Leu mutation. (1990) (49)
HIGH‐DOSE DESFERRIOXAMINE AS A CAUSE OF GROWTH FAILURE IN THALASSEMIC PATIENTS (1988) (48)
Fetal haemoglobin and malaria. (1976) (48)
Protecting Against Bad Air (2001) (48)
DNA rearrangements of immunoglobulin genes correlate with phenotypic markers in B-cell malignancies. (1984) (48)
Paroxysmal nocturnal haemoglobinuria. (2020) (48)
New somatic mutation in the PIG-A gene emerges at relapse of paroxysmal nocturnal hemoglobinuria. (1998) (47)
Comparison of GdA and GdB activities in Nigerians. A study of the variation of the G6PD activity. (1977) (47)
Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria (2016) (47)
Plasmodium falciparum malaria and human red cells. II. Red cell genetic traits and resistance against malaria. (1981) (46)
Two distinct patterns of glycosylphosphatidylinositol (GPI) linked protein deficiency in the red cells of patients with paroxysmal nocturnal haemoglobinuria (1992) (46)
Genetic variants of human erythrocyte glucose 6-phosphate dehydrogenase. I. Regulation of activity by oxidized and reduced nicotinamide-adenine dinucleotide phosphate. (1971) (46)
The Zinc Finger Gene ZIC2 Has Features of an Oncogene and Its Overexpression Correlates Strongly with the Clinical Course of Epithelial Ovarian Cancer (2012) (45)
Production and characterization of lymphoblastoid cell lines with the paroxysmal nocturnal hemoglobinuria phenotype. (1993) (44)
Decreased malaria morbidity in the Tharu people compared to sympatric populations in Nepal. (1988) (44)
The European Cancer Patient’s Bill of Rights, update and implementation 2016 (2016) (44)
The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH). (2006) (44)
G6PD mahidol, a common deficient variant in South East Asia is caused by a (163)glycine----serine mutation. (1989) (44)
Rare diseases and effective treatments: are we delivering? (2015) (44)
Two populations of erythroid cell progenitors in paroxysmal nocturnal hemoglobinuria. (1984) (43)
Solution of the structure of tetrameric human glucose 6-phosphate dehydrogenase by molecular replacement. (1999) (43)
Rearrangement of the T-cell receptor delta genes in human T-cell leukemias. (1989) (43)
The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement. (1988) (42)
A Role for PML in Innate Immunity. (2011) (42)
Cloning of the glucose 6-phosphate dehydrogenase gene from Plasmodium falciparum. (1994) (42)
Prospective analysis of minimal bone marrow infiltration in pediatric Burkitt's lymphomas by long-distance polymerase chain reaction for t(8;14)(q24;q32) (2003) (42)
α, β and γ T‐cell receptor genes: rearrangements correlate with haematological phenotype in T cell leukaemias (1987) (41)
Enzymic properties of different types of human erythrocyte glucose-6-phosphate dehydrogenase, with characterization of two new genetic variants. (1968) (41)
HEMOTOLOGICALLY IMPORTANT MUTATIONS : GLUSOSE-6-PHOSPHATE DEHYDROGENASE (1996) (41)
correspondence: Pregnancy in PNH: another eculizumab baby (2010) (41)
Alpha, beta and gamma T-cell receptor genes: rearrangements correlate with haematological phenotype in T cell leukaemias. (1987) (41)
Myelodysplasia in a patient with pre‐existing paroxysmal nocturnal haemoglobinuria: a clonal disease originating from within a clonal disease (1994) (40)
Deficiency in red blood cells (1991) (39)
Genetic variants of human erythrocyte glucose-6-phosphate dehydrogenase. Kinetic and thermodynamic parameters of variants A, B, and A- in relation to quaternary structure. (1976) (39)
Imbalance in X-chromosome expression: evidence for a human X-linked gene affecting growth of hemopoietic cells. (1979) (38)
G6PD is indispensable for erythropoiesis after the embryonic-adult hemoglobin switch. (2004) (38)
THE MALARIA/G.-6-P.D. HYPOTHESIS (1979) (38)
Patients with paroxysmal nocturnal hemoglobinuria have a high frequency of peripheral-blood T cells expressing activating isoforms of inhibiting superfamily receptors. (2005) (38)
Clinical and haematological consequences of recurrent G6PD mutations and a single new mutation causing chronic nonspherocytic haemolytic anaemia (1998) (38)
T-cell leukemias with rearrangement of the gamma but not beta T-cell receptor genes. (1988) (37)
cDNA sequences of human glucose 6-phosphate dehydrogenase cloned in pBR322 (1981) (37)
The Frequency of Granulocytes with Spontaneous Somatic Mutations: A Wide Distribution in a Normal Human Population (2013) (36)
Promoter function of the human glucose-6-phosphate dehydrogenase gene depends on two GC boxes that are cell specifically controlled. (1994) (36)
Relationship between the Genes for Glucose-6-phosphate Dehydrogenase and for Haemoglobin in a Nigerian Population (1968) (36)
Somatic-cell selection is a major determinant of the blood-cell phenotype in heterozygotes for glucose-6-phosphate dehydrogenase mutations causing severe enzyme deficiency. (1996) (35)
Genetic variants of human erythrocyte glucose 6-phosphate dehydrogenase. II. In vitro and in vivo function of the A- variant. (1971) (35)
Expression and characterization of glucose-6-phosphate dehydrogenase of Plasmodium falciparum. (1990) (35)
Genetic factors in malaria. (1974) (35)
Human glucose‐6‐phosphate dehydrogenase Lysine 205 is dispensable for substrate binding but essential for catalysis (1995) (34)
Favism in the African type of glucose-6-phosphate dehydrogenase deficiency (A-). (1990) (34)
COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy (2021) (34)
Glucose-6-Phosphate Dehydrogenase Deficiency. (1995) (33)
Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells. (2002) (33)
Factor V Leiden mutation investigated by amplification created restriction enzyme site (ACRES) in PNH patients with and without thrombosis. (1996) (32)
G6PD Aures: a new mutation (48 Ile-->Thr) causing mild G6PD deficiency is associated with favism. (1993) (32)
Genetic variation in the host and adaptive phenomena in Plasmodium falciparum infection. (1983) (32)
Establishment and characterization of three new malignant lymphoid cell lines (1987) (32)
Genetics of PNH (2000) (32)
Inherited haemolytic states: glucose-6-phosphate dehydrogenase deficiency. (1975) (31)
At least five polymorphic mutants account for the prevalence of glucose-6-phosphate dehydrogenase deficiency in Algeria (1994) (31)
Uracil in DNA in megaloblastic anemia. (1981) (31)
Neonatal jaundice and severity of glucose-6-phosphate dehydrogenase deficiency in Sardinian babies. (1987) (31)
Mild spherocytic hereditary elliptocytosis and altered levels of alpha- and gamma-adducins in beta-adducin-deficient mice. (2000) (30)
Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: Preliminary results (2009) (30)
Analysis of beta, gamma, and delta T-cell receptor genes in mycosis fungoides and Sezary syndrome. (1991) (30)
COVID-19 2022 update: transition of the pandemic to the endemic phase (2022) (30)
Glucose 6-Phosphate Dehydrogenase (G6PD) Deficiency (2001) (29)
A ten year review of the sickle cell program in Muhimbili National Hospital, Tanzania (2018) (29)
Genetic variants of human erythrocyte glucose 6‐phosphate dehydrogenase: new variants in West Africa characterized by column chromatography (1977) (29)
Feasibility of evaluating quality cancer care using registry data and electronic health records: a population-based study. (2012) (29)
The PNH abnormality in myeloproliferative disorders: association of PNH and acute erythremic myelosis in two children. (1979) (29)
Somatic mutations and the hierarchy of hematopoiesis (2010) (29)
Malaria and erythrocyte glucose-6-phosphate dehydrogenase variants in West Africa. (1979) (28)
Dyskeratosis congenita: three additional families show linkage to a locus in Xq28. (1993) (28)
Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. (2000) (28)
G6PD deficiency: a polymorphism balanced by heterozygote advantage against malaria. (2015) (28)
An extensive search for RFLP in the human glucose-6-phosphate dehydrogenase locus has revealed a silent mutation in the coding sequence. (1988) (28)
Glucose-6-phosphate dehydrogenase. (2020) (28)
Molecular genetics of glucose‐6‐phosphate dehydrogenase (G6PD) deficiency in Spain: identification of two new point mutations in the G6PD gene (1995) (28)
Two founder mutations in the SEC23B gene account for the relatively high frequency of CDA II in the Italian population (2011) (27)
Glycosylphosphatidylinositol-specific T cells, IFN-γ-producing T cells, and pathogenesis of idiopathic aplastic anemia. (2017) (27)
Severe telomere shortening in patients with paroxysmal nocturnal hemoglobinuria affects both GPI- and GPI+ hematopoiesis. (2003) (26)
G6PD deficiency and malaria selection (2011) (26)
Recommended methods for an additional red cell enzyme (pyrimidine 5'-nucleotidase) assay and the determination of red cell adenosine-5'-triphosphate, 2,3-diphosphoglycerate and reduced glutathione. International Committee for Standardization in Haematology. (1989) (26)
Genetic heterogeneity of "normal" human erythrocyte glucose-6-phosphate dehydrogenase: an isoelectrophoretic polymorphism. (1979) (26)
Genetic variants of human erythrocyte glucose-6-phosphate dehydrogenase. Discrete conformational states stabilized by NADP + and NADPH. (1973) (26)
PNH cells are as sensitive to T-cell-mediated lysis as their normal counterparts: implications for the pathogenesis of paroxysmal nocturnal haemoglobinuria. (2000) (25)
Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature (2012) (25)
Lymphomatoid granulomatosis--evidence of a clonal T-cell origin and an association with lethal midline granuloma. (1988) (25)
Causality and Chance in the Development of Cancer. (2015) (24)
Molecular basis of chronic non‐spherocytic haemolytic anaemia: a new G6PD variant (393 Arg→His) with abnormal KmG6P and marked in vivo instability (1992) (24)
Three major G6PD‐deficient polymorphic variants identified among the Mauritian population (1999) (23)
Causality and Chance in the Development of Cancer. (2015) (23)
The glucose-6-phosphate dehydrogenase (G6PD) deficient variant G6PD Union (454 Arg-->Cys) has a worldwide distribution possibly due to recurrent mutation. (1994) (22)
Severe malarial infection in a patient with sickle-cell anaemia. (1971) (22)
Glucose-6-phosphate Dehydrogenase Deficiency. Metabolic and Molecular Basics of Inherited Disease (2001) (22)
The production of normal and variant human glucose-6-phosphate dehydrogenase in cos cells. (1988) (22)
Transcriptional and epigenetic basis for restoration of G6PD enzymatic activity in human G6PD-deficient cells. (2014) (22)
Glycosylphosphatidylinositol‐linked proteins are required for maintenance of a normal peripheral lymphoid compartment but not for lymphocyte development (2002) (22)
Molecular heterogeneity underlying the G6PD Mediterranean phenotype (1992) (22)
Immunoglobulin gene rearrangements in hairy cell leukemia and other chronic B cell lymphoproliferative disorders. (1987) (21)
Genetically determined deficiency of glucose 6-phosphate dehydrogenase (type-A-) is expressed in the liver. (1979) (21)
Somatic mutations in cancer development (2011) (21)
Indolent cutaneous prodrome of fatal HTLV-I infection (1990) (21)
PNH cells are as sensitive to T‐cell‐mediated lysis as their normal counterparts: implications for the pathogenesis of paroxysmal nocturnal haemoglobinuria (2000) (21)
ERYTHROCYTE GLUCOSE 6‐PHOSPHATE DEHYDROGENASE DEFICIENCY (G6PD TYPE A‐) AND NEONATAL JAUNDICE (1976) (21)
SIZE OF POLYRIBOSOMES IN INTACT RETICULOCYTES. (1964) (20)
Independent origin of single and double mutations in the human glucose 6‐phosphate dehydrogenase gene (1996) (20)
Haemoglobinopathies including thalassaemia. Part 3. Sickle cell anaemia in tropical Africa. (1981) (20)
Polymerase chain reaction automated at low cost. (1988) (20)
Immunoglobin synthesis by fresh biopsy cells and established cell lines from Burkitt's lymphoma. (1968) (19)
Malaria. Protecting against bad air. (2001) (19)
Polyribosome metabolism in growing and nongrowing Escherichia coli. (1969) (19)
Regulation of glucose 6-phosphate dehydrogenase expression in CHO-human fibroblast somatic cell hybrids (1983) (19)
Studies of polymorphic traits for the characterization of populations. African populations south of the Sahara. (1973) (19)
Glucose metabolism in human erythrocytes from normal and fava bean-sensitive subjects. (1962) (19)
Favism, the commonest form of severe hemolytic anemia in Palestinian children, varies in severity with three different variants of G6PD deficiency within the same community. (2016) (19)
Childhood leukaemia and lymphoma: African experience supports a role for environmental factors in leukaemogenesis (2014) (19)
Physiology: Haemoglobin's chaperone (2002) (18)
PNH from mutations of another PIG gene. (2013) (18)
Glucose 6‐phosphate dehydrogenase deficiency and red cell membrane defects: additive or synergistic interaction in producing chronic haemolytic anaemia (1994) (18)
G6PD Kalyan and G6PD Kerala; two deficient variants in India caused by the same 317 Glu-->Lys mutation. (1992) (18)
Vχ gene segments rearranged in chronic lymphocytic leukemia are distributed over a large portion of the Vχ locus and do not show somatic mutation (1993) (18)
Paroxysmal nocturnal hemoglobinuria: Correction of abnormal phenotype by somatic cell hybridization (1993) (18)
Human red cell glucose-6-phosphate dehydrogenase is encoded only on the X chromosome (1990) (18)
Hydroxyurea - An Essential Medicine for Sickle Cell Disease in Africa. (2019) (18)
Escherichia coli: High Resistance or Dependence on Streptomycin Produced by the Same Allele (1968) (17)
ERYTHROCYTE GLUCOSE 6‐PHOSPHATE DEHYDROGENASE DEFICIENCY (G6PD TYPE A‐) AND NEONATAL JAUNDICE (1976) (17)
Characterization of glucose-6-phosphate dehydrogenase variants. II. G6PD Kephalonia, G6PD Attica, and G6PD "Seattle-like" found in Greece. (1969) (17)
Streptomycin Action: Greater Inhibition of Escherichia coli Ribosome Function with Exogenous than with Endogenous Messenger Ribonucleic Acid (1969) (17)
Retroviral-mediated gene transfer of a mutant H-ras gene into normal human bone marrow alters myeloid cell proliferation and differentiation. (1994) (17)
A simple disease with no cure (1989) (17)
Hematologically important mutations: glucose-6-phosphate dehydrogenase. (1996) (17)
Mendelian diseases among Roman Jews: implications for the origins of disease alleles. (1999) (17)
A third instance of the high oxygen affinity variant, HB heathrow [β103(G5)phe→leu]: Identification of the mutation by mass spectrometry and by DNA analysis (1991) (16)
Serum erythropoietin levels in paroxysmal nocturnal haemoglobinuria: implications for therapy (1996) (16)
Hypertensive disorders of pregnancy are associated with an inflammatory state: evidence from hematological findings and cytokine levels (2019) (16)
Genetic variants of glucose 6-phosphate dehydrogenase from human erythrocytes: unique properties of the A - variant isolated from "deficient" cells. (1972) (15)
Prolymphocytic leukemia of B cell type: rearranged immunoglobulin (Ig) genes with defective Ig production. (1985) (15)
Clonal origin of abnormal granulocytes in paroxysmal nocturnal hemoglobinuria [letter; comment] (1992) (15)
Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria (2014) (15)
GENETIC HETEROGENEITY AND PATHOPHYSIOLOGY OF G6PD DEFICIENCY (1974) (15)
ACQUIRED β THALASSAEMIA TRAIT IN MDS (1991) (15)
HTLV-1 provirus and mycosis fungoides. (1993) (15)
HAEMOGLOBINURIA AND HAPTOGLOBIN IN G6PD DEFICIENCY (1995) (15)
Paroxysmal murine Hemoglobinuria(?): A model for human PNH. (1999) (14)
Genetic heterogeneity of glucose 6-phosphate dehydrogenase deficiency in Sardinia (1980) (14)
Plasmodium falciparum malaria and human red cells. I. A genetic and clinical study in children. (1981) (14)
Protein synthesis in erythroid cells. 3. Monoribosome and polyribosome function in the cell-free system. (1965) (14)
When are parasites clonal? (1990) (14)
Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost (2020) (14)
Some acute phase proteins in Burkitt lymphoma in Nigerians. (1967) (13)
Anomalous rearrangements of the immunoglobulin heavy chain genes in human leukemias support the loop-out mechanism of class switch. (1992) (13)
Rhesus Immunization in Nigeria (1968) (13)
Sickle cell anaemia. A simple disease with no cure. (1989) (13)
ORIGIN OF G6PD POLYMORPHISM: MALARIA AND G6PD DEFICIENCY (1986) (13)
Analysis of beta, gamma, and delta T-cell receptor genes in lymphomatoid papulosis: cellular basis of two distinct histologic subsets. (1991) (13)
Synthesis of the essential core of the human glycosylphosphatidylinositol (GPI) anchor. (2011) (13)
High-level regulated expression of the human G6PD gene in transgenic mice. (1996) (13)
Innate resistance to malaria: the intraerythrocytic cycle. Commentary. (1990) (13)
Imatinib: can one outwit chronic myeloid leukemia? (2002) (12)
The “escape” model: a versatile mechanism for clonal expansion (2019) (12)
The heart in eosinophilic leukaemia. (1970) (12)
DNA rearrangements of cell lineage specific genes in lymphoproliferative disorders. (1986) (12)
Defects in DNA and globin messenger RNA in homozygotes for hemoglobin Lepore. (1979) (12)
A new genetic polymorphism in the 16S ribosomal RNA gene of human motochondrial DNA (1989) (12)
Frontiers in medicine: Gene transfer and gene therapy (1992) (11)
Monoclonal gammopathy (Waldenström's macroglobulinaemia) producing specific red cell antibody. (1976) (11)
Glucose 6‐phosphate dehydrogenase: Genetic and haematological aspects (1987) (11)
KERNICTERUS IN G.-6-P.D.-DEFICIENCY (1966) (11)
Tafenoquine for the prophylaxis, treatment and elimination of malaria: eagerness must meet prudence. (2019) (11)
Paroxysmal nocturnal hemoglobinuria: significant association with specific HLA-A, -B, -C, and -DR alleles in an Italian population. (2008) (11)
Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania. (2021) (11)
In vivo gene marking of rhesus macaque long‐term repopulating hematopoietic cells using a VSV‐G pseudotyped versus amphotropic oncoretroviral vector (2004) (11)
Coexistence of three hemoglobins with different alpha-chains in two unrelated children (with family studies indicating polymorphism in the number of alpha-globin genes in the Sardinian population). (1980) (11)
SickleInAfrica. (2020) (11)
Expression of Plasmodium falciparum G6PD‐6PGL in laboratory parasites and in patient isolates in G6PD‐deficient and normal Nigerian children (2003) (10)
New developments in glucose-6-phosphate dehydrogenase deficiency. (1973) (10)
Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations (2016) (10)
Erythrocyte enzymes in neonatal juandice. (1976) (10)
Partial purification and characterization of the messenger RNA for human glucose-6-phosphate dehydrogenase. (1984) (10)
V kappa gene segments rearranged in chronic lymphocytic leukemia are distributed over a large portion of the V kappa locus and do not show somatic mutation. (1993) (9)
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria (2013) (9)
Intracranial ventricular haemorrhage as a first presentation of haemophilia. A case of successful surgical management. (1969) (9)
Intragenic interspecific complementation of glucose 6-phosphate dehydrogenase in human-hamster cell hybrids (1990) (9)
Allogeneic bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. (2000) (9)
Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization. (2006) (9)
Treating Rare Diseases in Africa: The Drugs Exist but the Need Is Unmet (2022) (9)
X-chromosome inactivation: Switching off blocks of genes (1983) (9)
Congenital dyserythropoietic anaemia type II associated with a new type of G6PD deficiency (G6PD Gabrovizza). (1984) (9)
NEW CLINICAL AND BIOCHEMICAL FINDINGS FROM 235 PATIENTS WITH HEMOGLOBIN LEPORE (1980) (9)
Resolution of genetic variants of human erythrocyte glucose 6-phosphate dehydrogenase by thin-layer chromatography. (1967) (9)
About hemoglobins, G6PD and parasites in red cells (1995) (9)
The osmotic fragility of red cells in newborns and infants. (1970) (9)
Genetic factors in favism (1982) (9)
ANALYSIS OF THE PRIMARY STRUCTURE OF HUMAN G6PD DEDUCED FROM THE cDNA SEQUENCE (1986) (9)
Synthesis of haemoglobins specified by allelic genes in human heterozygotes. (1971) (9)
Haematology in Africa (2011) (8)
Favism and Glucose-6-Phosphate Dehydrogenase Deficiency. (2018) (8)
Leukaemia is a genetic disorder of somatic cells. (1990) (8)
Clonal origin of abnormal granulocytes in paroxysmal nocturnal hemoglobinuria. (1992) (8)
Glucose 6-phosphate dehydrogenase expression is less prone to variegation when driven by its own promoter. (2001) (8)
Somatic mutation in paroxysmal nocturnal hemoglobinuria. (1997) (8)
Paroxysmal nocturnal hemoglobinuria (PNH) in the eculizumab era: The bedside and beyond. (2008) (8)
Genetic variants of human erythrocyte glucose 6-phosphate dehydrogenase: automated procedure for characterization by column chromatography. (1980) (8)
Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition. (2022) (7)
Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) (2010) (7)
Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease. (2021) (7)
Sickle cell disease and malaria: decreased exposure and asplenia can modulate the risk from Plasmodium falciparum (2020) (7)
Acquired beta thalassaemia trait in MDS. (1991) (7)
New genetic variants of glucose 6‐phosphate dehydrogenase (G6PD) in Italy (1981) (7)
Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria. (2015) (7)
The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria. (2006) (7)
Glucose-6-phosphate dehydrogenase and other genetic factors interacting with drugs. (1986) (7)
Mild clinical expression of S- b thalassemia in a Brazilian patient with the b + IVS-I-6 (T ® C) mutation (1998) (6)
Congenital dyserythropoietic anemia type II in human patients is not due to mutations in the erythroid anion exchanger 1. (2003) (6)
High resolution of proteins by double-inverted gradient polyacrylamide gel electrophoresis (DG-PAGE). (1994) (6)
Haemophilia in Nigeria. (1970) (6)
Frequency of Missense Mutations in the Coding Region of a Eukaryotic Gene Transferred by Retroviral Vectors (2002) (6)
X-linked somatic-cell selection and polycythemia rubra vera. (1984) (6)
PNH phenotypes and their genesis (2020) (6)
Linkage disequilibrium of polymorphic sites in the G6PD gene in African populations and the origin of G6PD A-. (1991) (6)
A PvuII restriction fragment length polymorphism of the glucose-6-phosphate dehydrogenase gene is an African-specific marker (1990) (6)
DNA haplotypes in Africans and West Indians with sickle cell anaemia or SC disease. (1996) (6)
Tseudo‐lymphoid‘ leukaemia with unusual features: Ultrastructural, immunological, cytogenetic and molecular studies (1987) (6)
F cell numbers are associated with an X‐linked genetic polymorphism and correlate with haematological parameters in patients with sickle cell disease (2020) (6)
Leukaemia: a genetic disorder of haemopoietic cells. (1993) (5)
Haematology in tropical areas. (1981) (5)
The effect of magnesium ion on carbohydrate interconversion: action on the aldolase equilibrium. (1962) (5)
Seroconversion of human T cell lymphotrophic virus III (HTLV-III) in patients with haemophilia: a longitudinal study. (1985) (5)
One enzyme from two genes? (1989) (5)
Hemolytic anemia. (1999) (5)
Familial erythrocytosis with over-production of erythropoietin. (2008) (5)
Management of pregnancy when maternal blood has a very high level of fetal haemoglobin (1994) (5)
Control of hemolysis in patients with PNH. (2021) (5)
Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease (2020) (5)
Genetic and Biochemical Heterogeneity of β‐Thalassaemia in Naples (1980) (5)
Clonal rearrangement of the T‐cell receptor γ gene associated with a bizarre lymphoproliferative syndrome (1988) (5)
High frequency of acquired aplastic anemia in Tanzania (2019) (5)
DOMINANT Β-THALASSEMIA TRAIT DUE TO A NOVEL INSERTION (1992) (4)
Integrated cancer control: the case for comprehensive cancer care networks (CCCN) (2017) (4)
Limited Exchange Transfusion Can Be Very Beneficial in Sickle Cell Anemia with Acute Chest Syndrome: A Case Report from Tanzania (2018) (4)
[Evaluation of iron overload in thalassemia]. (1986) (4)
REARRANGEMENT OF THE T-CELL RECEPTOR DELTA (TCR-DELTA GENES IN HUMAN T-CELL LEUKEMIAS (1988) (4)
Haemolytic anaemias due to enzyme deficiencies. (1991) (4)
Interactions between Genetic Red‐Cell Defects and the Environment (1975) (4)
The mechanisms of neoplastic transformation. (2001) (4)
Severe hemolytic anemia associated with the homozygous state for an unstable hemoglobin variant (Hb Bushwick). (1995) (4)
Sterile ‘Abscess’ of the Spleen and the Sickle Cell Trait (2018) (4)
TMPRSS2:ERG fusion gene and androgen-ablation therapy in prostate cancer. (2010) (4)
Pyruvate kinase deficiency: characterization of two new genetic variants. (1982) (4)
GROWTH RETARDATION IN SICKLE-CELL DISEASE (1985) (4)
OP04 Safety and efficacy of the terminal complement inhibitor eculizumab in patients with paroxysmal nocturnal hemoglobinuria: Shepherd Phase III clinical study results (2007) (3)
Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion: Clinical Improvement with Eculizumab Therapy. (2007) (3)
Effect of insulin on xylose transport in human leukocytes (1960) (3)
Malaria and Darwinian Selection in Human Populations (2004) (3)
The "n-1" model for myelodysplastic syndromes. (1992) (3)
Effects of Eculizumab Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Concurrent Immunosuppressive Therapy for Bone Marrow Insufficiency. (2009) (3)
Sickle cell disease, malaria and dengue fever: a case of triple jeopardy (2019) (3)
The genomic breakpoint in a patient with Philadelphia-positive acute leukemia is 5' of the breakpoint cluster region. (1988) (3)
Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria (2021) (3)
Genes expressed in red cells could shape a malaria attack. (2018) (3)
[Drugs for rare diseases: the blessing of being orphans.] (2019) (3)
Advances in Brief T b RI ( 6 A ) Is a Candidate Tumor Susceptibility Allele 1 (1999) (3)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (3)
[Psychological aspects of thalassemia]. (1986) (3)
Vitamin E and beta-thalassaemia. (1983) (2)
Introduction: from the genetic basis of blood disorders to gene transfer for the purpose of gene therapy. (1998) (2)
Italian slur rebutted (1984) (2)
PNH cells are hard to kill (2002) (2)
From Mendel to a Mendelian disorder: towards a cure for sickle cell disease (2022) (2)
The Molecular Basis of Anemia (2010) (2)
Of mice and men: From hematopoiesis in mouse models to curative gene therapy for sickle cell disease (2022) (2)
Specifi'c defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria (2005) (2)
Cerebrospinal fluid immunoglobulins in Burkitt lymphoma. (1968) (2)
Microscopic haematuria. Dipsticks may pick up haemoglobinuria. (1994) (2)
Thrombolytic Therapy for Reversal of Thrombosis In Paroxysmal Nocturnal Hemoglobinuria (PNH) (2010) (2)
A third instance of the high oxygen affinity variant, Hb Heathrow [beta 103(G5)Phe- greater than Leu]: identification of the mutation by mass spectrometry and by DNA analysis. (1991) (2)
PREGNANCY IN ABNORMAL HAEMOGLOBINS CC, S‐THALASSAEMIA, SF, CF, DOUBLE HETEROZYGOTES (1972) (2)
The prevalence of human immunodeficiency and of hepatitis B viral infections is not increased in patients with sickle cell disease in Tanzania (2021) (2)
QUANTITATIVE EVALUATION OF THE ALKALINE GLYCEROPHOSPHATASE ACTIVITY OF THE LIVER DURING DEVELOPMENT AND OF THE MEDIUM USED FOR ITS CULTURE IN VITRO (1959) (2)
Blood diseases in Africa: Redressing unjust disparities is an urgent unmet need (2022) (2)
17 Glucose-6-Phosphate Dehydrogenase Defi ciency (2010) (2)
David Galton and the evolution of somatic cell populations (2007) (1)
[Succinic dehydrogenase activity in the kidney of Mus musculus albinus; histochemical research with neotetrazolium]. (1956) (1)
Neutral evolution in paroxysmal nocturnal (2008) (1)
Genetic Polymorphism of the Complement Receptor-1 (CR1) Gene Correlates with the Clinical Response to Eculizumab of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) (2012) (1)
Response to Nance letter. (1977) (1)
Administration of vitamin E in heterozygous beta-thalassaemia: the effect on red blood cell survival. (1984) (1)
Human albumin variants. Proposals for a nomenclature. (1982) (1)
Diagnostic and therapeutic implements based on advanced Biotechnology should be available in low-income countries (2019) (1)
[Non-oxidative heptose formation from glucose-6-phosphate in various experimental tumors]. (1957) (1)
Auto-Reactive Glycosyl-Phosphatidyl-Inositol (GPI) Specific T Cells Are Present in Most Patients with Idiopathic Aplastic Anemia (IAA) (2015) (1)
hemoglobin switch G6PD is indispensable for erythropoiesis after the embryonic-adult (2008) (1)
RED CELLS, IRON, AND ERYTHROPOIESIS Transcriptional and epigenetic basis for restoration of G6PD enzymatic activity in human G6PD-de ﬁ cient cells (2014) (1)
Selective Splenic Artery Embolization for the Treatment of Thrombocytopenia and Hypersplenism in Paroxysmal Nocturnal Hemoglobinuria (PNH) (2012) (1)
Safety and efficacy of eculizumab with concomitant erythropoietin therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH) (2007) (1)
treated by eculizumab patients mechanism of disease in paroxysmal nocturnal hemoglobinuria Complement fraction 3 binding on erythrocytes as additional (2013) (1)
COVID-19 2022 update: transition of the pandemic to the endemic phase (2022) (1)
Switching off blocks of genes. (1983) (1)
Genetic Heterogeneity of (1979) (1)
Gene transfer and gene therapy. (1992) (1)
[Thalassemia and malaria selection]. (1981) (1)
Diagnosis and clinical management of enzymopathies. (2021) (1)
[Transketolase activity in some transplantable tumors in mice]. (1960) (1)
Correction: Somatic mutations in cancer development (2011) (1)
IMMUNOGLOBULIN GENE REARRANGEMENT IN LYMPHOCYTIC-LEUKEMIA (1984) (1)
The Role of Lymphoid Cells in the Pathogenesis of PNH (2003) (1)
X-linked Wiskott-Aldrich syndrome in a girl. (1998) (1)
A T‐CELL LYMPHOMA OF SUPPRESSOR PHENOTYPE ARISING IN A PATIENT WITH SEVERE APLASTIC ANAEMIA (1989) (1)
Review in translational hematology Diagnosis and management of paroxysmal nocturnal hemoglobinuria (2005) (1)
Natural Killer-Like T (NKT) Cells with Specific T Cell Receptor (TCR) Sequences May Be Causally Implicated in the Pathogenesis of Paroxysmal Nocturnal Hemoglobinuria (PNH). (2004) (1)
Rearrangement of T-cell Receptor (Delta, Gamma and Beta) Genes and its Significance in T-cell Chronic Leukaemias. (1991) (1)
Emergent treatments for β-thalassemia and orphan drug legislations. (2022) (1)
. Glucose 6-Phosphate Dehydrogenase Deficiency: Genetics, Pharmacogenetics, and Malaria Selection (2012) (1)
[Membrane defects in paroxysmal nocturnal hemoglobinuria]. (1991) (1)
Molecular biology of parasites (1983) (1)
Complement Activation in Paroxysmal Nocturnal Hemoglobinuria (PNH) Causes Oxidative Damage Which May Affect Response to Eculizumab (2014) (1)
Immuno gene therapy comes into its own (1997) (1)
Paroxysmal nocturnal hemoglobinuria. (1989) (1)
C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab (2008) (0)
Nucleoside phosphorylase activity in guinea pig polymorphonuclear leukocytes (1962) (0)
Recent advances in haematology, immunology and blood transfusion, S. R. Hollán, I. Bernát, G. Füst, G. Gárdos and B. Sarkadi (Eds), Wiley, Chichester, 1983. No. of pages: xiv + 419 (Incl. Subject index). Price: £22.00. ISBN 0 471 90164 4 (1984) (0)
Good Pregnancy Outcome in a Patient Affected by Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab. (2009) (0)
Table of Contents (1995) (0)
Splenomegaly in Adolescents and Adults with Sickle Cell Anemia in Tanzania Is Associated with Less Severe Disease (2017) (0)
Book Review The Haemolytic Anaemias, Volume 5: Drug- and chemical-induced haemolytic anaemias; paroxysmal nocturnal haemoglobinuria; haemolytic disease of the newborn Third edition. By Sir John Dacie. 448 pp., illustrated. New York, Churchill Livingstone, 1999. $175. 0-4430-6269-2 (1999) (0)
Mendelian inheritance (1989) (0)
[The consumption of glucose in normal human subjects and those with a history of favism]. (1961) (0)
Continuous Cultures of Plasmodium Falciparum Established in Tanzania from Patients with Acute Malaria (2021) (0)
Closing remarks (2022) (0)
DRIFT INSTABILITIES IN CYLINDRICAL DISCHARGES INVOLVING BOTH IONS AND ELECTRONS (2003) (0)
Primaquine-induced haemolysis in females heterozygous for G6PD deficiency (2018) (0)
Protein structure: one enzyme from two genes? (1989) (0)
Management of paroxysmal nocturnal hemoglobinuria (PNH) (2022) (0)
HLA B*1402, Cw*0802 Haplotype and DRB1*1501 Allele Are Significantly Increased in Italian Paroxysmal Nocturnal Hemoglobinuria Affected Patients. (2007) (0)
Polymorphic sites intheAfrican population detected bysequence analysis oftheglucose-6-phosphate dehydrogenase geneoutline theevolution ofthevariants A andA- (1991) (0)
Human Red Cells With Paroxysmal Nocturnal Haemoglobinuria Phenotype Are Competent For The Growth Of Plasmodium falciparum (1999) (0)
[Oncogenesis: theories and facts]. (2015) (0)
[Causality and chance in oncogenesis]. (2015) (0)
Investigation of the DNA of the human malaria parasite P. falciparum by in vitro cloning into phage lambda (1983) (0)
What future for tropical disease research? (1985) (0)
[Magnesium & reactions of interconversion of glucides & ribose-5-phosphate in the rat liver]. (1957) (0)
Clinical Significance of G6PD Variants among Palestinians (2016) (0)
Genetic rearrangements in leukaemia and lymphoma: edited by Goldman J. M. & Harnden D.G. (Churchill Livingstone, London, 1986) 179 pages. ISBN 0-443-03102-9. Price: £44.00 (1987) (0)
Orphan drugs – Authors' reply (2019) (0)
[Mechanism of action of magnesium ions on the interconversion of carbohydrates]. (1958) (0)
Book Review Principles of Molecular Medicine Second edition. Edited by Marschall S. Runge and Cam Patterson. 1268 pp., illustrated. Totowa, NJ, Humana Press, 2006. $195. 978-1-58829-202-5 (2007) (0)
Management of paroxysmal nocturnal haemoglobinuria in the eculizumab era: the bedside and beyond (2008) (0)
[Decrease of adrenal ascorbic acid by massive doses of nicotinamide]. (1957) (0)
Tissue-specific Regulation of Human Glucose-6-phosphate-dehydrogenase (g6pd) Gene-transcription (1993) (0)
[Oxidation of triose phosphates in hemolysates of erythrocytes of normal human subjects and those with histories of favism]. (1961) (0)
Two Distinct but Functionally Related Autoreactive T Cell Populations in Paroxysmal Nocturnal Hemoglobinuria and Idiopathic Aplastic Anemia: Glycosylphosphatidylinositol-Specific and IFNγ-Producing T Cells (2017) (0)
Persistenceofexpressionofthe TMPRSS2:ERGfusiongeneafter pre-surgeryandrogenablationmaybeassociatedwithearly prostatespecificantigenrelapseofprostatecancer: Preliminaryresults (2009) (0)
Department of Error (2019) (0)
53 – MODIFICATION OF A HISTOKINETTE FOR USE AS AN AUTOMATED PCR MACHINE (1989) (0)
RED CELLS , IRON , AND ERYTHROPOIESIS Glycosylphosphatidylinositol-speci fi c , CD 1 d-restricted T cells in paroxysmal nocturnal hemoglobinuria (2013) (0)
The molecular basis of bone marrow failure syndromes and red cell enzymopathies (2019) (0)
Faculty Opinions recommendation of Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. (2012) (0)
[Effect of acute inanition on the ascorbic acid content of the adrenals & liver in guinea pig]. (1957) (0)
Diagnosis and clin i cal man age ment of enzymopathies (2021) (0)
1 Diagnosis and Management of Paroxysmal Nocturnal Hemoglobinuria : (2005) (0)
Role of the Somatic Mutation Rate in Patients with Classical Myeloproliferative Neoplasms (MPN) with and without Other Neoplasms (2012) (0)
FROM PROTEIN STRUCTURE AND FUNCTION TO MOLECULAR PATHOLOGY (1995) (0)
Current Topics in Hematology, Volume 5 : Edited by S. Piomelli and S. Yachnin Alan Liss; New York, 1985 180 pages. £26.00 (1985) (0)
An unusual case of familial aplastic anaemia: in vitro and in vivo evidence for a multipotent progenitor responsive to G–CSF (1998) (0)
MECHANISM OF ACT/'ON OF STIREPTOM'YCIN IN E. COLI: INTERRUPTION OF TIHE RIBOSOME CYCLE AT THE INITIATION (2016) (0)
Complement in PNH and other hemolytic anaemias 1 (2017) (0)
LETTERS TO THE EDITOR (1977) (0)
Autoreactive T Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Specifically Recognize Glycosyl- Phosphatidyl-Inositol (GPI) (2012) (0)
Genetic variants of human glucose 6 phosphate dehydrogenase studies of turnover and glucose 6 phosphate dehydrogenase specific messenger rna (1982) (0)
Genetic and biochemical heterogeneity of beta-thalassaemia in Naples. (1980) (0)
The pattern of thalassemia in Naples. (1982) (0)
GENERAL DISCUSSION: HUMAN PROTEINS. (1964) (0)
Chapter 11. Paroxysmal Nocturnal Haemoglobinuria (2007) (0)
Comprehensive Cancer Care Networks: A realistic model for optimising outcomes and minimising inequalities (2016) (0)
Blood companions (1988) (0)
Severe congenital neutropenia with elastase, neutrophil expressed (ELANE) gene mutation in a Tanzanian child (2021) (0)
Faculty of 1000 evaluation for Thrombosis in paroxysmal nocturnal hemoglobinuria. (2016) (0)
Paroxysmal nocturnal haemoglobinuria (PNH)iscaused bysomatic mutations inthePIG-Agene (1994) (0)
Genetic Factors in Malaria Resistance (2000) (0)
Clinicopathologic Conference**Presented at King Faisal Specialist Hospital and Research, Centre, 23 April 1984. (1985) (0)
[Comparative and critical studies on photochemical determination of ascorbic acid with methylene blue and with dinitrophenylhydrazine]. (1957) (0)
East and West (1991) (0)
Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common (2012) (0)
Human Immunodeficiency and Hepatitis B Viral Infections Among Patients With Sickle Cell Disease in Dar Es Salaam City, Tanzania: A Descriptive Study (2021) (0)
Tropical medicine: recent advances in malaria and other protozoal diseases. (1983) (0)
CD157 plays a prominent role in neutrophil physiology (2005) (0)
Focus on: gene therapy in oncology. Introduction. (1998) (0)
Gene rearrangements in human pathology (1986) (0)
Clonal Origin and Clonal Selection in PNH (2017) (0)
Mice with hematopoiesis deficient in glycosyl phosphatidylinositol (GPI) linked molecules: A possible model for paroxysmal nocturnal hemoglobinuria(PNH) (1996) (0)
The spectrum of molecular lesions in human tumors. (2003) (0)
Safety and efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria evolving from patients with myelodysplastic syndrome and aplastic anemia (2007) (0)
18 Paroxysmal nocturnal hemoglobinuria (2007) (0)
COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy (2021) (0)
100 and 50 years ago (2002) (0)
Lack of correlation of eculizumab therapy in paroxysmal nocturnal hemoglobinuria (PNH) patients with myeloproliferative disorders, myelodysplastic syndromes, acute leukemias or aplastic anemia with long-term treatment (2008) (0)
[Fructose-1, 6-diphosphatase in Ehrlich carcinoma; absence of a specific phosphatase]. (1959) (0)
Running title: CD157 mediates neutrophil adhesion and migration. (2013) (0)
High incidence of malaria in patients with sickle cell disease (2022) (0)
Resistance to "castration-resistant". (2014) (0)
[Magnesium & glucide interconversion reactions in the solid form of Ehrlich carcinoma]. (1958) (0)
Paroxysmal nocturnal hemoglobinuria: clinical expression and response to treatment are modified by a unique interaction with co-existing glucose 6-phosphate dehydrogenase deficiency (2014) (0)
FETAL HÆMOGLOBIN AND MALARIA (1976) (0)
Specific methylation pattern atthe3'endofthehuman housekeeping geneforglucose 6-phosphate dehydrogenase (1995) (0)
underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria Abnormal T-cell repertoire is consistent with immune process (2010) (0)
Cloning, Clones and Clonal Disease (2000) (0)
Faculty Opinions recommendation of Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. (2010) (0)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (0)
complement-mediated hemolysis and C3 fragment paroxysmal nocturnal hemoglobinuria erythrocytes from The complement receptor 2/factor H fusion protein TT30 protects (2012) (0)
[Behavior of glucose-6-phosphatase & acid & alkaline phosphatases in the Ehrlich solid carcinoma]. (1957) (0)
Evaluation of risk for development of myeloproliferative disorders, myelodysplastic syndromes, or acute leukemias with long-term eculizumab therapy in paroxysmal nocturnal hemoglobinuria (PNH) patients (2007) (0)
Department of Error (2019) (0)
Complement-mediated oxidative damage of red cells impairs response to eculizumab in a G6PD-deficient patient with PNH. (2020) (0)
Table of Contents (1984) (0)
Faculty of 1000 evaluation for Biosynthesis, remodelling and functions of mammalian GPI-anchored proteins: recent progress. (2016) (0)
Hemoglobin Switching: Edited by G. Stamatoyannopoulos and A.W. Nienhuis; Alan R. Liss; New York, 1989; part B, xxiv + 468 pages; $120.00 each (1990) (0)
Inherited and acquired mutations in blood diseases. (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lucio Luzzatto?

Lucio Luzzatto is affiliated with the following schools: